Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
March 2019
-
Story People and Culture
Enabling 130,000 employees to grow in an organization committed to continuous learning
Our Chief Learning Officer, Simon Brown, talks about our ongoing efforts to build new capabilities by investing in our own people.
-
Media Release
Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16… -
Media Release
Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early… -
Story Access to Healthcare
Novartis Access impact evaluation: progress update on our work with Boston University
Boston University developed a methodology to evaluate the impact of Novartis Access in Kenya. Peter C. Rockers tells us about the ongoing study.
February 2019
-
Media Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 22nd consecutive dividend increase to CHF 2.85 (+2%) per share for 2018; representing a 3.1% yield and approximately 57% payout of free cash flow Overwhelming majority of… -
Media Release
Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrates gut
Die Aktionäre bewilligen die 22. Dividendenerhöhung in Folge. Für 2018 wird die Dividende auf CHF 2.85 (+2%) je Aktie erhöht, was einer Rendite von 3,1% und einem Anteil von etwa 57% des freien… -
Media Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée générale
Les actionnaires approuvent la 22e hausse consécutive du dividende à CHF 2.85 (+2%) par action pour 2018, soit un rendement de 3,1% et une distribution du free cash-flow d'environ 57% Une… -
In The News
Novartis is flipping the pyramid, explains Steven Baert
In this episode of CNN`s special HR series, Steven Baert, Chief People & Organization Officer, shares the challenges that Novartis is facing as it turns its management style on its head and… -
Story From Our Labs
How a 19th-century technology is speeding up drug discovery
Pneumatic tube systems have existed for 150+ years and have transported everything from telegrams to aircraft parts. Now they’re being used in our labs.
-
Key Release
Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off
Basel, February 25, 2019 - Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of… -
Media Release
Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)
Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea… -
Media Release
Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO Fascioliasis, commonly known as liver…